Press Releases

All Press Releases

Immunosuppressive Therapy Increases Risk of Cardiovascular Incident

September 17, 2019

Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating atherosclerosis with immunotherapy may increase cardiovascular risk, demonstrating the immune nature of atherosclerosis.

CardioVax Announces Name Change to Abcentra

January 30, 2019

CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therapeutics for inflammatory diseases, announced today that it has changed its name to Abcentra.